IBD Evidence

Artikulua

Zerk eragiten du IBD? Genetika, ingurumena eta gorakada

Eguneratuta 3 min irakurri 60 aipamenak

Hodien endoskopia sarea goiko gastrointestinal eta kolon polipektomiarako erabiltzen da
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Ez genetikak ez ingurumenak bakarrik azaltzen dute hesteetako hanturazko gaixotasuna. Genetikak zure ahultasuna nor duen esaten dizu; epidemiologiak esaten dizu ahultasunak bakarrik ezin duela istorio osoa izan, gaixotasunaren mundu-mapa geneek azal dezaketena baino askoz azkarrago mugitu delako.

Genetikak zer erakusten duen benetan

Genoma osoko asoziazio-ikerketek hesteetako hanturazko gaixotasunerako ahultasunarekin lotutako lokus kopuru handi bat identifikatu dute. Asoziazio-datuen meta-analisi batek 38 ahultasun-lokus identifikatu zituen eta populazioen artean partekatutako arrisku genetikoa azpimarratu zuen, eta, aipagarria dena, neurri batean beste immunitate-bidezko gaixotasun batzuekin partekatua [25]. Genoma osoko beste asoziazio-ikerketa batek zehazki hainbat integrina-genetan immunitate-aktibazioa inplikatu zuen [24] — mekanikoki emaitza interesgarria, integrina blokeatzen duten sendagaiek (gure tratamendu-orrian jasotako anti-integrina klase biologikoak) gene horiek dauden leuzozito-trafikatze bide zehatza etenez funtzionatzen dutelako.

Genetikaren ondorio praktikoa jendeak espero duena baino mugatuagoa da. Hesteetako hanturazko gaixotasuna ez da gene bakarreko, herentzia mendeliarreko gaixotasun bat — poligenikoa da, lokus askorekin, bakoitzak arrisku-kopuru txiki bat ekarriz. Lehen mailako senide bat izateak hesteetako hanturazko gaixotasunarekin arriskua populazio orokorraren gainetik igotzen du, baina gaixotasunarekin lotutako aldaera genetikoak dituzten pertsonen gehiengo handiak ez du inoiz gaixotasuna garatzen. Genetikak ahultasun-atalase bat ezartzen du; beste zerbaitek erabakitzen du atalase hori gainditzen den ala ez.

Zergatik ezin den genetika istorio osoa izan

Populazio baten egitura genetikoa ez da dekada gutxi batzuetan aldatzen. Hesteetako hanturazko gaixotasunaren munduko intzidentzia bai. Nature aldizkarian 2025ean argitaratutako azterketa batek hesteetako hanturazko gaixotasunaren intzidentzia jarraitzen du, berak epidemiologia-faseak deitzen dienetan zehar — intzidentzia baxua, intzidentzia bortizki igotzen den azelerazio-fase bat, eta gero prebalentzia-oreka konposizio-fase bat, non intzidentzia platuratzen den baina gaixotasunarekin bizi diren pertsonen kopuruak gora egiten jarraitzen duen, kronikoa delako [35]. Gaur egun industrializatzen ari diren eskualdeak Europa Mendebaldeak eta Ipar Amerikak XX. mendean zehar igaro zuten azelerazio-fase beretik igarotzen ari dira.

Eredu hori lehenago dokumentatu zen munduko intzidentzia eta prebalentziari buruzko populazioan oinarritutako ikerketen berrikuspen sistematiko batean [23], eta terapia aurreratuen aroan adin guztietako epidemiologia zehazki lantzen duen beste berrikuspen batek egungo munduko egoera kokatzen du [33]. Haurtzaroan hasitako hesteetako hanturazko gaixotasunean zentratutako berrikuspen sistematiko batek joera azeleratzaile bera aurkitu zuen zehazki haur eta nerabeengan [15], eta aldi berean ospitaleratze-joerak aldi-analisiak dituen beste berrikuspen sistematiko batean karakterizatu ziren [7].

Deriba genetikoa baino industrializazioa jarraitzen duen eredu geografiko eta tenporal bat da eskura dagoen argumenturik sendoena, populazio batek bizi den moduari buruzko zerbaitek — ez soilik jaiotzeko moduak — kausa-lanaren zati handi bat egiten duela erakusteko.

Ingurumen-hautagaiak

Meta-analisien gainbegirako berrikuspen batek hesteetako hanturazko gaixotasunaren ingurumen-arrisku-faktoreak zuzenean aztertu zituen, banakako esposizio-ikerketa askotako ebidentzia sintesi bakar batean bilduz [20]. Literatura honen laburpen zintzoa da hautagai batzuek indar desberdineko ebidentzia dutela, eta bakar batek ere ez duela bere kabuz nahikoa dela frogatu — modu koherentean gaixotasun batekin, ziurrenik ahultasun genetikoa duen pertsona batek esposizio-konbinazio jakin bat aurkitu behar duenarekin.

Balio bakarra: piezak nola uztartzen diren

Faktore-kategoriaZer dago ezarritaZer ez dagoen
Ahultasun genetikoaHamarnaka lokus laguntzaile identifikatuta; arriskua familietan pilatzen da eta mekanismoak partekatzen ditu beste immunitate-gaixotasun batzuekinEz dago gene bakar bat beharrezkoa edo nahikoa denik; genetikoki ahulak diren gehienek ez dute inoiz hesteetako hanturazko gaixotasuna garatzen
Eredu geografikoa/tenporalaIntzidentzia bortizki igotzen da eskualdeak industrializatu ahala, gero platuratzen da prebalentziak gora egiten jarraitzen duen bitarteanEredu horrek ingurumenak garrantzia duela erakusten du; bere kabuz ez du identifikatzen zein esposiziok duen garrantzi handiena
Banakako ingurumen-esposizioakGainbegirako berrikuspen batek hautagai-faktore askotako esposizio-literatura sintetizatu duEz dago ingurumen-faktore bakar bat bere kabuz beharrezko edo nahikotzat ezarrita dagoenik
ElkarrekintzaSinesgarria eta datu-eredu orokorrarekin koherentea: ahultasuna gehi esposizioaEzin da zuzenean neurtu egungo ikerketa-diseinuekin, banakako mailan

Zergatik den hau garrantzitsua era praktikoan

Honek ez du kudeaketa aldatzen. Ez du identifikatzen saihestu beharreko elikagairik, gaixoaldiak prebenitzen dituela bermatzen duen bizimodu-aldaketarik, edo banakako arriskua zehaztasun erabilgarriarekin aurreikusten duen probarik. Azaltzen duena da pazienteei maiz modu inkoherentean esaten zaizkien bi gauza: hesteetako hanturazko gaixotasuna ez dela dietak edo estresak modu sinplean "eragiten" (genetikak eta populazio-mailako ingurumen-aldaketek eguneroko aukerek baino kausa-lan askoz gehiago egiten dute), eta ez dela ere zorte genetiko txarra hutsa (gaur egun industrializatzen ari diren eskualdeetako intzidentzia gero eta handiagoak horixe baztertzen du bere kabuz). Berrargitalpen horiek biek pazienteek adierazten duten errua murrizten dute, "zer egin dut hau eragiteko" galderaren inguruan — ebidentzia-baseak ez du benetan babesten jokabide bakar bati buruz galdetzea.

Ohiko galderak

Hesteetako hanturazko gaixotasuna herentzia bidezkoa al da? Nire seme-alabek izango al dute?
Hesteetako hanturazko gaixotasuna duen norbaiten lehen mailako senideetan arriskua handiagoa da, baina senideen gehiengo handiak ez du inoiz garatzen. Ahultasun-gene eredu bat da, ez herentzia mendeliarreko gaixotasun bat.
Jandako edo egindako zerbaitek eragin al zuen nire hesteetako hanturazko gaixotasuna?
Ez dago elikadura- edo bizimodu-faktore bakar bat kausa nahikotzat ezarrita dagoenik. Ebidentziak ahultasun genetikoaren eta populazio-mailako ingurumen-esposizioen konbinazio bat adierazten du, urteetan zehar garatzen dena, ez identifikagarria den banakako eragile bat.
Zergatik ari da hesteetako hanturazko gaixotasuna ohikoagoa bihurtzen lehen arraroa zen herrialdeetan?
Honek industrializazioa nahiko gertutik jarraitzen du ingurumen-osagai baten aldeko argumenturik sendoenetako bat izateko — geneak ez dira aski azkar aldatzen hori azaltzeko, eta eredua orain hainbat eskualdetan eta garaitan dokumentatu da.
Genetikak sentikortasuna soilik azaltzen badu, zein da benetako abiarazlea?
Ez da zehaztasunez ezarri. Ingurumen-esposizio hautagaiak sintetizatu dira berrikuspen orokor baten ebidentzian, baina ez da frogatu faktore bakar bat ere beharrezkoa edo nahikoa denik — hau ikerketa-eremu irekia da oraindik, ez erabakitako galdera bat.
Hiru kamera-kapsula, hestegorria, heste meharra eta heste lodia irudikatzeko erabiliak
Irensten diren kapsulek heste meharreko zatiak argazkitatzen dituzte, endoskopio arrunt batek iritsi ezin dituenak. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons

Lotutako irakurketa

Orri honen atzean dagoen froga 30 argitalpenen ikerketa motaren arabera osaketa erakusten duen barra pilatua. 2563meta-analysis (25)randomised trial (6)review (3)other (1)
35 argitalpen, 2015–2026. Horrek probak eta sintesiak biltzen dituen nahasketa bat da, eta horretatik kausaren inguruko baieztapen bat egiteko arrazoizkoa den posizioa da. Iturria: orri honen aipamen zerrenda, behean.

Erreferentziak

Hemen azpiko aipamen guztiak PubMed-en edo DOI bidezko jatorrizko peer-reviewed erregistroari lotzen diote. Hemen ez dago mediku aholkurik ordezkatzeko.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Mediterranean diet in treatment of inflammatory bowel disease: A systematic review and meta-analysis Singh A, Rana U, Chandnani S, et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026 · Meta-analysis DOIPubMed 41803562
  3. Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study Gregersen L, Moos C, Hikmat Z, et al. · Advances in nutrition (Bethesda, Md.) · 2026 · Systematic review DOIPubMed 41825595Full text
  4. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  5. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  6. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  7. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  8. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  9. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. Pre-Illness Index-Based Dietary Patterns and Inflammatory Bowel Disease Risk: A Systematic Review and Meta-Analysis Meng F, Zhang T, Meng X, et al. · Nutrition reviews · 2025 · Meta-analysis DOIPubMed 40700526
  12. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  13. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials Kuźmin L, Kubiak K, Lange E · Nutrients · 2025 · Systematic review DOIPubMed 40573159Full text
  14. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  15. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  16. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  17. Efficacy of different dietary therapy strategies in active pediatric Crohn's disease: a systematic review and network meta-analysis Ma J, Chong J, Qiu Z, et al. · PeerJ · 2024 · Meta-analysis DOIPubMed 39686992Full text
  18. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  19. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  20. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  21. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  22. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  23. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  24. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  25. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  26. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  27. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  28. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  29. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  30. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  31. Systematic Review of the Effects of Oat Intake on Gastrointestinal Health Valido E, Stoyanov J, Bertolo A, et al. · The Journal of nutrition · 2021 · Systematic review DOIPubMed 34486656
  32. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  33. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  34. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  35. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  36. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  37. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  38. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  39. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  40. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  41. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419
  42. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  43. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  44. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis Zhou XL, Xu W, Tang XX, et al. · BMC gastroenterology · 2014 · Meta-analysis DOIPubMed 25002150Full text
  45. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial Wellens J, Vanderstappen J, Hoekx S, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Randomised controlled trial DOIPubMed 40816342
  46. A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease Yap JM, Wall CL, Meredith-Jones K, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 41829955Full text
  47. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study Minato I, Mena P, Ricciardiello L, et al. · Molecular nutrition & food research · 2025 · Randomised controlled trial DOIPubMed 40255128Full text
  48. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study Delgarm P, Mokhtare M, Ebrahimi Daryani N, et al. · Scientific reports · 2025 · Randomised controlled trial DOIPubMed 41315628Full text
  49. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  50. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial Pasta A, Formisano E, Calabrese F, et al. · European journal of clinical investigation · 2025 · Randomised controlled trial DOIPubMed 39853756
  51. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  52. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  53. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  54. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition Svolos V, Hansen R, Nichols B, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 30550821
  55. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  56. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  57. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  58. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  59. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  60. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text

Orri hau automatikoki itzuli da ingelesez. Aipamenak eta zenbakiak aldatu gabe daude. Irakurri ingelesezko jatorrizkoa ezer arraro irakurtzen bada. Irakurri ingelesezko jatorrizkoa